MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 922 productos para "MAPK".
Filtrar por
Porcentaje de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Precio más bajo
- Precio más alto
- Pureza más baja
- Pureza más alta
- Entrega estimada más rápida
KRAS G12C inhibitor 60
KRAS G12C Inhibitor 60 (compound 23), a selective inhibitor targeting the Kras-G12C mutation, is utilized in the investigation of lung, colorectal, andFórmula:C31H30F5N7O2Pureza:98%Forma y color:SolidPeso molecular:627.61HPK1-IN-4
CAS:HPK1-IN-4 is an HPK1 (MAPK41) inhibitor with an IC 50 of 0.061 nM. HPK1-IN-4 is often used as a preclinical immunotherapy tool compound.Fórmula:C23H26N6O3Pureza:97.06%Forma y color:Yellow SolidPeso molecular:434.4909Pan-RAS-IN-6
Pan-RAS-IN-6 (compound 24) serves as a DUSP6 inhibitor, effectively reducing MAPK activation in the NCI-H1373-Luc model (DUSP6). It concurrently exhibits notable tumor growth inhibition and regression in the NSCLC brain metastasis mouse model. The compound displays high selectivity and potent inhibitory effects, particularly on KRAS mutation-associated signaling pathways. It demonstrates varied inhibitory activities against distinct KRAS mutants and their interacting proteins. The IC 50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively.Fórmula:C46H60N8O5SForma y color:SolidPeso molecular:837.08MEK/RAF-IN-1
MEK/RAF-IN-1 (Compound 16b) serves as an inhibitor targeting both MEK and RAF, demonstrating potent efficacy with IC 50 values reported at 28 nM for MEK1, and 3 nM for both BRAF and BRAFV600E. This compound exhibits significant antitumor capabilities, effectively curbing cell proliferation in vitro in MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Furthermore, MEK/RAF-IN-1 significantly restricts tumor growth in xenograft mouse models employed in the study of colorectal cancer.Fórmula:C28H29F3N6O5SForma y color:SolidPeso molecular:618.63Klotho-derived peptide 1 hydrochloride
Klotho-derived peptide 1 (KP1 human) hydrochloride inhibits the interaction between TGF-β and TGF-β receptor 2, suppressing the activation of TGF-β-induced Smad2/3 and mitogen-activated protein kinase (MAPK). Additionally, it exhibits antifibrotic and renal protective effects in mouse models.Forma y color:Odour SolidNK7-902 TFA
NK7-902 TFA is a CRBN molecular glue degrader of NEK7. It effectively degrades NEK7 in human primary monocytes and whole blood, yet only partially inhibits NLRP3-dependent IL-1β production. While NK7-902 TFA achieves deep and lasting NEK7 degradation, it temporarily blocks NLRP3 inflammasome activation in non-human primates when administered orally. Additionally, NK7-902 TFA demonstrates activity in mouse systems.Forma y color:Odour SolidMitogen-activated protein kinase 1
CAS:Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.Pureza:98%Forma y color:SolidHSND80
HSND80 (Compound 1) is an orally active MNK/p70S6K inhibitor, exhibiting a Kd value of 44 nM for MNK1 and 4 nM for MNK2. The residence time of HSND80 on MNK1 and MNK2 is 45 minutes and 58 minutes, respectively. HSND80 effectively inhibits non-small cell lung cancer (NSCLC) both in vitro and in vivo, and suppresses the growth of triple-negative breast cancer (TNBC) cells in vitro.Forma y color:Odour SolidNUCC-0200808
NUCC-0200808 (Compound 12g) is an MNK1 inhibitor with an IC50 of 42 nM. It reduces eIF4E phosphorylation and cell viability in AML cells and induces apoptosis. NUCC-0200808 shows potential for research in the field of leukemia.Forma y color:Odour SolidCobimetinib (R-enantiomer)
CAS:Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib which is a selective MEK inhibitor.Fórmula:C21H21F3IN3O2Pureza:98%Forma y color:SolidPeso molecular:531.318MAPK Inhibitor Library
A unique collection of xnum cancer cell differentiation inducing compounds for high throughput and high content screening;Forma y color:Odour SolidBI1701963
BI1701963 is an orally effective inhibitor that targets the SOS1 and KRAS interaction, specifically inhibiting the activation of KRAS by blocking its GTP loading. This compound is utilized in cancer research to explore potential therapeutic effects against KRAS-driven malignancies.Fórmula:C47H62N8O4SForma y color:SolidPeso molecular:835.11KRAS G12C inhibitor 20
CAS:KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.Fórmula:C33H37ClFN7O3Forma y color:SolidPeso molecular:634.14Fluconazole-PEG6-XMU-MP-9
Fluconazole-PEG6-XMU-MP-9, PEG-linked conjugate, fluconazole antifungal plus XMU-MP-9, promotes Nedd4-1 mediated K-Ras mutant degradation.Fórmula:C48H53F3N10O10SPureza:98.73%Forma y color:Yellow SolidPeso molecular:1019.06PPARγ agonist-21
PPARγagonist-21 (Compound 9a) is a PPARγ agonist with an EC50 of 3.12 μM. It inhibits NF-κB by activating PPAR-γ and reduces the assembly of the NLRP3 inflammasome. PPARγagonist-21 blocks interactions between NLRP3-ASC and NLRP3-NEK7, alleviating the severity of gouty arthritis.Setidegrasib
CAS:Setidegrasib is a PROTAC-mediated KRAS degrader (DC50: 37 nM). Setidegrasib induces the ubiquitination and proteasomal degradation of the oncogenic protein.Fórmula:C60H65FN12O7SPureza:98.28% - 99.80%Forma y color:White SolidPeso molecular:1117.30TAT-PAK18 R192A
TAT-PAK18 R192A is an inactive Tat-Pak peptide. It does not influence Rac1 translocation triggered by any tested proteins.Fórmula:C143H247N55O37Peso molecular:3326.91369(RS)-G12Di-1
(RS)-G12Di-1 is a selective covalent inhibitor of K-Ras-G12D.Fórmula:C37H35FN6O4Forma y color:SolidPeso molecular:646.27038KRAS-IN-43
KRAS-IN-43 (Compound 9) is a broad-spectrum KRAS inhibitor with IC50 values of 0.15 μM for KRASG12V, 0.14 μM for KRASG12C, and 0.47 μM for wild-type KRAS. It disrupts the interaction between KRAS and cRAF and suppresses ERK phosphorylation. KRAS-IN-43 shows potential for research in KRAS mutation-associated cancers, including pancreatic, colorectal, and lung cancers.Forma y color:Odour SolidZ16078526
CAS:Z16078526 promotes Ucp1, p38 MAPK, lipolysis, thermogenic genes, and mitochondrial activity in mouse brown adipocytes.Fórmula:C18H17N3O4SPureza:99.18%Forma y color:SolidPeso molecular:371.41
